Abstract
Blood-based biomarkers (BBM) for Alzheimer’s disease (AD) are being increasingly used in clinical practice to support an AD diagnosis. In contrast to traditional diagnostic modalities, such as amyloid positron emission tomography and cerebrospinal fluid biomarkers, BBMs offer a more accessible and lower cost alternative for AD biomarker testing. Their unique scalability addresses the anticipated surge in demand for biomarker testing with the emergence of disease-modifying treatments (DMTs) that require confirmation of amyloid pathology. To facilitate the uptake of BBMs in clinical practice, The Global CEO Initiative on Alzheimer’s Disease convened a BBM Workgroup to provide recommendations for two clinical implementational pathways for BBMs: one for current use for triaging and another for future use to confirm amyloid pathology. These pathways provide a standardized diagnostic approach with guidance on interpreting BBM test results. Integrating BBMs into clinical practice will simplify the diagnostic process and facilitate timely access to DMTs for eligible patients.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Michelle M. Mielke,
Matthew Anderson,
J. Wesson Ashford,
Andreas Jeromin,
Pei‐Jung Lin,
Allyson Rosen,
Jamie Tyrone,
Lawren Vandevrede,
Deanna R. Willis,
Oskar Hansson,
Ara S. Khachaturian,
Suzanne E. Schindler,
Joan Weiss,
Richard Batrla,
Sasha Bozeat,
John R. Dwyer,
Drew Holzapfel,
Daryl Rhys Jones,
James F. Murray,
Katherine A. Partrick,
Emily Scholler,
George Vradenburg,
Dylan Young,
Joel B. Braunstein,
Samantha C. Burnham,
Fabricio Ferreira de Oliveira,
Yan Helen Hu,
Soeren Mattke,
Zul Merali,
Mark Monane,
Marwan Noel Sabbagh,
Eli Shobin,
Michael Weiner,
Chinedu T. Udeh‐Momoh | October 1, 2024